개요
우울증이라고도 불리는 주요우울장애(MDD)는 세계적으로 가장 심각하고 흔한 정신질환 중 하나입니다. 지속적인 슬픔, 흥미와 기쁨의 상실, 기력 저하, 식욕과 수면의 저하, 심지어 자살을 특징으로 하며, 일상적인 활동과 심리사회적 기능에 장애를 일으킵니다.
MDD는 기분 저하를 특징으로 하는 질환으로, 유전, 스트레스, 호르몬 불균형, 알코올 및 약물 사용, 특정 질환, 특정 약물, 어린 시절의 학대 등 다양한 요인에 의해 유발될 수 있습니다. 정확한 원인은 밝혀지지 않았지만, 이러한 요인들은 MDD 발병 위험을 증가시킬 수 있습니다.
시장 역학: 시장 성장 촉진요인과 시장 성장 억제요인
기술적 발전으로 인한 치료 옵션의 부상
지난 20년 동안 주요우울장애(MDD)의 치료법은 큰 진전을 이루었습니다. 우울증은 개인차가 있다는 인식이 확산되면서 개인의 신경화학적 불균형을 파악하고 진단하여 그에 따라 치료를 조정하려는 노력이 이루어지고 있습니다.
증거에 기반한 치료, 특히 약물 치료의 발전이 이루어지고 있습니다. 시탈로프람, 에스시탈로프람, 플루옥세틴, 셀트랄린 등 보다 선택적이고 특수한 항우울제가 개발되어 효과가 향상되고 부작용이 줄어들었습니다. 약물치료와 심리치료, 특히 인지행동치료와 정신역동치료를 병행하는 것이 가장 효과적인 치료법으로 알려져 있습니다.
만성통증, 정신과, 간질, 말초신경계 및 중추신경계 질환의 미충족 수요를 해결하기 위해 신경세포 흥분성 장애에 대한 새로운 치료법을 개발하는 임상 단계의 생명공학 기업 엘리엠 테라퓨틱스(Eliem Therapeutics, Inc.)는 ETX -155 임상 프로그램 추진 계획에 대한 최신 정보를 제공했습니다.
또한, 라이프스타일의 변화로 인한 일과 삶의 균형이 깨지고 MDD 환자 수가 증가하면서 예측 기간 동안 MDD 치료제 시장을 견인할 것으로 예상되는 주요 요인입니다. 또한, 세계 제약사들의 MDD 치료제 공동 개발 및 공동 판매를 위한 제휴, 신약 개발, 정부의 적절한 상환 정책 등도 MDD 치료제 시장의 성장을 가속하고 있습니다.
시장 역학: 시장 성장 억제요인
대우울증(MDD)은 우울증 이상의 증상을 유발할 수 있습니다. 건강에 영향을 미치고 사고와 행동을 변화시키는 합병증을 유발할 수 있습니다. 합병증으로는 체중 증가, 비만, 만성 질환, 만성 통증, 자해 행위, 인지 기능의 변화 등이 있습니다.
그러나 신약 승인에 대한 각국 정부의 엄격한 규제, 일부 블록버스터 의약품의 특허 만료, 다른 약물과의 합병증 위험, 주요 우울장애 치료제 관련 부작용 등이 예측 기간 동안 주요 우울장애 치료제 시장의 성장을 저해하고 있습니다.
목차
제1장 조사 방법과 조사 범위
제2장 정의와 개요
제3장 주요 요약
제4장 시장 역학
제5장 산업 분석
- Porter의 Five Forces 분석
- 공급망 분석
- 가격 분석
- 규제 분석
- 러시아·우크라이나 전쟁의 영향 분석
- DMI의 견해
제6장 COVID-19 분석
제7장 약제 유형별
- 항우울제
- 비정형 항우울제
- 항정신병약
- 신경 조절약
제8장 투여 경로별
제9장 유통 채널별
제10장 지역별
- 북미
- 유럽
- 남미
- 아시아태평양
- 중동 및 아프리카
제11장 경쟁 구도
- 경쟁 시나리오
- 시장 현황/점유율 분석
- 인수합병(M&A)분석
제12장 기업 개요
- Eli Lilly and Company
- 기업 개요
- 제품 포트폴리오와 설명
- 재무 개요
- 주요 동향
- Allergan
- Alkermes
- Lundbeck
- Johnson & Johnson
- Pfizer, Inc
- AstraZeneca plc
- Merck & Co
- GlaxoSmithKline plc
- Sanofi S.A
- Takeda Pharmaceutical Company Limited(*LIST NOT EXHAUSTIVE)
제13장 부록
LSH
Overview
Major depressive disorder (MDD) also referred to as depression, is one of the most severe and common psychiatric disorders across the world. It is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.
MDD is a condition characterized by mood swings, which can be triggered by various factors such as genetics, stress, hormone imbalance, alcohol or drug use, certain medical conditions, specific medications, and childhood abuse. The exact cause is unknown, but these factors can increase the risk of developing MDD.
Market Dynamics: Drivers and Restraints
Rise in technological advancements in treatment options
Over the past two decades, significant progress has been made in the treatment options for major depressive disorder (MDD). It is now recognized that depression varies from person to person, and efforts are being made to identify and diagnose the specific neurochemical imbalances in individuals to tailor treatment accordingly.
Advances have been made in evidence-based treatments, particularly in drug therapy. More selective and specialized antidepressants, such as citalopram, escitalopram, fluoxetine, and sertraline, have been developed, offering improved efficacy and fewer side effects. Combining drug therapy with psychotherapy, specifically cognitive-behavioral and psychodynamic therapy, has been shown to be the most effective approach.
For instance, Eliem Therapeutics, Inc a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, provided an update on its plans to advance its ETX-155 clinical program.
Furthermore, Work life imbalances due to lifestyle changes, and an increase in the MDD patient pool are the key drivers expected to drive the MDD treatment market over the forecasted period. Partnerships for co-development and co-marketing of MDD drugs among drug manufacturers across the globe, the development of new drugs, and adequate government reimbursement policies have also fueled the growth of the MDD treatment market.
Market Dynamics: Restraint
Major depressive disorder (MDD) can cause more than depression. It can lead to complications that affect your health and change how you think and behave. Some of the complications include weight gain and obesity, chronic illness, chronic pain, self-harm, cognitive changes and others.
However, stringent regulations imposed by various governments for new drug approval, patent expiries of some blockbuster drugs, risk of complications with other medications, and related side effects of major depressive disorder drugs hamper the growth of the major depressive disorder treatment market over the forecasted period.
Segment Analysis
The global major depressive disorder is segmented based on drug type, route of administration, distribution channel and region.
The Antidepressants from the drug type segment accounted for approximately 41.2 % of the market share
The Antidepressants from the drug type segment accounted for approximately 41.2 % and it is expected to be dominated during the forecast period. Antidepressants are psychiatric drugs which are licensed to treat depression. Some are also licensed to treat other conditions, such as anxiety disorders phobias, bulimia (an eating disorder), and some physical conditions, including managing long-term pain.
For instance, in December 2022 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.
Moreover, in September 2022 Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced positive results from a phase III clinical trial in Japan of brexpiprazole in the treatment of major depressive disorder. The late-stage trial evaluated the efficacy and safety of brexpiprazole as adjunctive therapy in 740 adult patients in Japan, aged 20 to 64 years, with major depressive disorder. Brexpiprazole was administered once daily for six weeks, in 1 mg or 2 mg doses, as an adjunctive therapy to SSRI or SNRI antidepressants, for patients who previously had inadequate responses to antidepressant monotherapy.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to an increase in the number of patients suffering from major depressive disorder, advancement in technology to develop new therapeutic drugs, rise in the ongoing clinical trials, advanced healthcare infrastructure and among others are expected to dominate by this region during the forecast period.
For instance, according to clinicaltrails.gov in September 2022 Janssen Research & Development, LLC started clinical studies on a Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) which is under phase 3 with 840 active participants have been enrolled and these studies have been going in Alabama United states.
Moreover, according to clinicaltrails.gov on November 2022 Otsuka Pharmaceutical Development & Commercialization, Inc started a clinical study on a Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder which is under Phase 3 with 900 enrolled participants and this studies currently going in New York United States.
COVID-19 Impact Analysis
COVID-19 had a substantial impact on major depressive disorder where according to studies published on the Impact of the COVID-19 pandemic on major depressive disorder in acute psychiatric inpatients where the studies focused on the relationship between COVID-19 and mental disorders reported results similar to those summarized above about psychiatric symptoms in the general population.
In particular, a large systematic review and meta-analysis found an increase of 27.6% in the prevalence of major depressive disorder (MDD) after the outbreak of the COVID-19 pandemic (COVID-19 Mental Disorders Collaborators, 2021) with a peak of the incidence from March to May 2020 in conjunction with the first restriction measures.
Market Segmentation
By Drug Type
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Dopamine Norepinephrine Reuptake Inhibitor
- Serotonin Norepinephrine Reuptake Inhibitor
- Serotonin Modulators
- Monoamine oxidase inhibitors (MAOIs)
- Others
- Atypical Antidepressants
- Antipsychotics
- Neuromodulators
By Route of Administration
- Oral
- Intravenous
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the major depressive disorder market include: Eli Lilly and Company, Allergan, Alkermes, Lundbeck, Johnson & Johnson, Pfizer, Inc, AstraZeneca plc, Merck & Co, GlaxoSmithKline plc, Sanofi S.A and among others.
Key Developments
- In September 2023 Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3, long-term, open-label, registrational trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).
- In August 2023 Biogen Inc. and Sage Therapeutics, Inc announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD.
- In May 2023 - BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced positive top-line data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film.
Why Purchase the Report?
- To visualize the global major depressive disorder market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous major depressive disorder market-level data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global major depressive disorder market report would provide approximately 69 tables, 70 figures, and 185 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Drug Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Driver
- 4.1.1.1. Rise in technological advancements in treatment options
- 4.1.2. Restraints
- 4.1.2.1. Complications associated with the disease
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. By Drug Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 7.1.2. Market Attractiveness Index, By Drug Type
- 7.2. Antidepressants*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Atypical Antidepressants
- 7.4. Antipsychotics
- 7.5. Neuromodulators
8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Oral*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Intravenous
- 8.4. Parenteral
9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies
10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.7.1. Germany
- 10.3.7.2. UK
- 10.3.7.3. France
- 10.3.7.4. Italy
- 10.3.7.5. Spain
- 10.3.7.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.5.1. China
- 10.5.5.2. India
- 10.5.5.3. Japan
- 10.5.5.4. Australia
- 10.5.5.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
12. Company Profiles
- 12.1. Eli Lilly and Company
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Allergan
- 12.3. Alkermes
- 12.4. Lundbeck
- 12.5. Johnson & Johnson
- 12.6. Pfizer, Inc
- 12.7. AstraZeneca plc
- 12.8. Merck & Co
- 12.9. GlaxoSmithKline plc
- 12.10. Sanofi S.A
- 12.11. Takeda Pharmaceutical Company Limited (*LIST NOT EXHAUSTIVE)
13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
